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Abstract: A high HLA expression in uveal melanoma (UM) is part of the prognostically unfavorable
inflammatory phenotype. We wondered whether the presence of soluble HLA (sHLA) in the aqueous
humour is associated with clinical, histopathological or genetic tumour characteristics, and represents
tumour HLA expression and intratumoural inflammation. Aqueous humour from 108 UM patients
was analysed for the presence of sHLA, using a Luminex assay specific for HLA Class I. Clinical and
genetic parameters were compared between sHLA-positive and negative eyes. A qPCR analysis was
performed on tumour tissue using a Fluidigm assay. In 19/108 UM-containing eyes, the sHLA level in
the aqueous was above the detection limit. Tumours in sHLA-positive eyes were significantly larger,
more frequently involved the ciliary body, and more often showed monosomy 3, gain of chromosome
8q and loss of BAP1 staining. Melanoma-related survival was worse in patients with sHLA-positive
aqueous humour. sHLA in the aqueous did not represent the tumour’s HLA expression and did not
relate to immune cell infiltration in the tumour. We conclude that UM-containing eyes may contain
sHLA in the aqueous humour, where it is a prognostically-unfavourable sign and may influence local
immune responses.
Keywords: uveal melanoma; soluble HLA; infiltrate; aqueous humour; liquid biopsies;
immunotherapy
1. Introduction
Although rare, with an incidence varying between 5.0 per million in the United States of America
to 9.5 per million in Northern Europe, uveal melanoma (UM) is the most common primary ocular
malignancy in adults [1,2]. The metastatic route of UM is mainly hematogenous, with about 50% of
UM patients developing metastases, which occur predominantly in the liver [3,4]. Important genetic
prognostic parameters are the monosomy of chromosome 3 (M3), a gain of the long arm of chromosome
8 (8q) [5] and a mutation in the BRCA1-Associated Protein 1 (BAP1) gene [6–10].
Prognostically-infaust tumours often carry an inflammatory phenotype, which is characterised by
infiltrating lymphocytes and macrophages and a high expression of HLA Class I [11–13]. The relation
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between a high HLA Class I expression in UM and an increased risk of developing metastases
has been reported [11,12,14–18]. HLA expression is an important prerequisite for T cell-mediated
immunotherapy, and information on a tumour’s HLA expression may therefore help to identify cases
that are good candidates for T cell-mediated therapy; for example, with IMCgp100 (Immunocore gp100
TCR-based bispecific T cell redirector) [19].
Information regarding the HLA expression level of the tumour might be obtained by studying the
non-cell bound or soluble version of HLA (sHLA) in the aqueous humour. The presence of soluble
HLA was first found in plasma of healthy HLA-A2 positive individuals in a study in 1970 in Leiden,
The Netherlands [20]. The sHLA complex consists of an α chain which is non-covalently bound to
β2-microglobulin. Soluble HLA may result from shedding from the cell membrane, by proteolytic
cleavage of membrane-bound proteins or from alternative splice variants, leading to a secreted version
of sHLA molecules [21].
Since its discovery, sHLA has been determined in different body fluids, including blood, plasma,
amniotic fluid, seminal plasma, synovial fluid, sweat, urine and peritoneal dialysate. Levels of
sHLA have been studied in the context of acute and chronic graft-versus-host disease, preeclampsia,
rheumatoid arthritis and chronic renal failure [22–26]. In patients with varicella meningitis, sHLA
was detected in the cerebrospinal fluid (CSF); in patients with AIDS, the concentration of sHLA in
both serum and CSF directly correlated to the stage of the disease, with a higher concentration in
more advanced cases [27]. Levels of circulating sHLA Class I molecules differ per person based on the
presence of disease, as well as the inherited HLA haplotype [28]. sHLA may have immunomodulatory
effects [29]: The level of sHLA correlates to the progression rate of several malignant diseases, and the
shedding of sHLA molecules is considered a mechanism for evasion by tumour cells from immune
recognition [30].
For enucleated UM patients, prognostic information comes from the tumour’s size, and its
chromosome and mutation status. Knowledge regarding the immune status of the tumour and its
HLA expression may one day be useful in deciding whether immunotherapy may be appropriate as
adjuvant therapy to prevent metastases.
We developed and optimised an assay to assess sHLA Class I in small amounts of anterior chamber
fluid and determined whether we can detect this in the aqueous humour of UM-containing eyes.
The assay recognises the soluble version of HLA Class I. Our data show that it is possible to determine
sHLA Class I levels in the aqueous humour of UM eyes, and that the presence of sHLA is related to
survival, but that this is more related to the presence of a large, anteriorly-located tumour than to the
expression of HLA on the tumour cells.
2. Results
2.1. Patient Demographics
A high expression of HLA antigens on UM cells is an indicator of inflammation and of a bad
prognosis. We wondered whether analysis of sHLA molecules in aqueous humour can be used to
indirectly determine HLA expression as an indicator of the presence of an inflammatory phenotype in
the tumour, and whether sHLA expression in the aqueous humour is higher in eyes with a high-risk
UM. Using a newly-developed Luminex assay, we measured sHLA in aqueous humour samples of 108
UM-containing eyes and observed measurable levels in 19/108 (18%). We compared the characteristics
of these 19 sHLA-positive cases with those of the 89 sHLA-negative cases (see Table 1 for patient and
tumour characteristics).
The tumours in the sHLA-positive group were thicker, with a mean tumour prominence of 9.8
mm (SD = 2.2 mm) versus a mean prominence of 7.0 mm (SD = 2.9 mm) in the sHLA-negative group
(p < 0.001), and more often involved the ciliary body (p < 0.001). Tumours from the sHLA-positive
group belonged to higher American Joint Committee on Cancer (AJCC) stages (p < 0.001).
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Table 1. Characteristics of patients with a uveal melanoma (UM) that underwent enucleation in the
Leiden University Medical Center (LUMC) between 1999 and 2016 (n = 108), categorised as soluble
HLA (sHLA) negative or sHLA positive, based on the level of sHLA in the aqueous humour.
Clinical and Histopathologic Characteristics
Patients, n (%) a
sHLA Negative (n = 89) sHLA Positive (n = 19) p-Value *
Gender
0.09 bFemale 33 (37) 11 (58)
Male 56 (63) 8 (42)
Previous tumour treatment prior to enucleation
0.69 dNo 86 (97) 18 (95)
Yes 3 (3) 1 (5)
Eye
0.28 bOD 52 (58) 7 (37)
OS 37 (42) 12 (63)
Age at enucleation
0.46 ein years, mean (±S.D.) 59 (±14) 63 (±16)
Eye colour c (known in 58 cases)
0.056 bLight 49 (88) 10 (67)
Dark 7 (12) 5 (33)
Largest basal tumour diameter
0.40 ein mm, mean (±S.D.) (known in 107 cases) 12.3 (±3.1) 13.1 (±3.1)
Tumour prominence
<0.001 e,*in mm, mean (±S.D.) (known in 107 cases) 7.0 (±2.9) 9.8 (±2.2)
Ciliary body involvement
<0.001 b,*No 64 (72) 5 (26)
Yes 25 (28) 14 (74)
Mitotic count f (known in 101 cases)
0.44 emean (±S.D.) 4.7 (±3.3) 6.4 (±7.1)
Histopathologic cell type
0.064 bSpindle cell 28 (32) 2 (11)
Epithelioid or mixed cell type 61 (69) 17 (89)
Bruch’s membrane (known in 104 cases)
0.076 d
Unclear 10 (12) 5 (26)
Intact 21 (25) 1 (5)
Broken 53 (62) 13 (68)
AJCC Stage, 8th edition
<0.001 d,*
I 11 (14) 0 (0)
IIA 29 (36) 0 (0)
IIB 23 (29) 6 (40)
IIIA, IIIB, IIIC 17 (21) 8 (53)
IV 0 (0) 1 (7)
Monosomy 3 status (known in 103 cases)
0.034 b,*D3 37 (44) 3 (17)
M3 48 (57) 15 (83)
8q status (known in 95 cases)
0.003 b,*No gain of 8q 35 (45) 1 (6)
Gain of 8q 43 (55) 16 (94)
Duplication of chromosome 6p (known in 82
cases)
0.98 bNo gain of 6p 31 (46) 7 (37)
Gain of 6p 36 (54) 8 (42)
Nuclear BAP1 staining (known in 97 cases)
0.036 b,*Normal 29 (37) 2 (11)
Absent 50 (63) 16 (89)
Metastases (known in 107 cases)
0.029 b,*Absent 52 (59) 6 (32)
Present 36 (41) 13 (68)
Vital status
0.36 d
Dead due to UM metastases 34 (38) 11 (58)
Average follow-up time, months 50 27
Dead due to other cause 19 (21) 0 (0)
Alive at last follow-up date 36 (40) 8 (42)
* Test is significant at the 0.05 level (2-tailed). Significant p values are shown in bold. a Percentages are rounded
and may not total 100; b Pearson χ2 test; c light eye colours: blue, grey, green, hazel—dark eye colour: brown;
d linear-by-linear association; e Mann–Whitney U Test; f number of mitoses per mm2 with 40× magnification, in
eight high power fields.
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With regard to chromosome status, the sHLA-positive group showed significantly more often
monosomy 3 (15/18, 83%) compared to the sHLA-negative group (48/85, 57%) (p = 0.034). Additionally,
the sHLA-positive group more frequently showed gain of 8q (16/17, 94%) as opposed to the
sHLA-negative group (43/78, 55%, p = 0.003), but no difference was observed with regard to chromosome
6p (p = 0.98). A total of 16/18 (89%) of the tumours in the sHLA-positive group had lost BAP1 staining,
which was significantly different from the 50/79 (63%) tumours in the sHLA-negative group (p = 0.036).
2.2. sHLA in Aqueous Humour Is Related to Survival
Metastases occurred more frequently in the sHLA-positive group, with 13/19 (68%) patients
developing metastases versus 36/88 (41%) patients in the negative group (p = 0.029, Table 1).
The melanoma-related survival was significantly worse in the sHLA-positive group (Log-Rank,
p = 0.025) (Figure 1).
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Figure 1. Kaplan–Meier survival curve sho ing elanoma-related survival, since enucleation, based
on the sHLA expression in the aqueous humour of 108 UM patients. Curves represent the negative and
positive sHLA groups. Both groups differ significantly in survival (Log Rank test p = 0.025).
2.3. Tumour HLA Expression and Infiltrate in the Tu our, eter ined by a Fluidigm qPCR Assay
To determine HLA expression and infiltrate in UM tissue, a Fluidigm quantitative real-time
PCR assay was performed on a subset of 89 tumours, of which the RNA was of sufficient quality.
When comparing the tumours’ HLA-A, HLA-B and β2M expression between the sHLA-negative
and sHLA-positive groups, no significant differences were found (p = 0.07, p = 0.46 and p = 0.60,
respectively) (Table 2).
Table 2. Expression of diff rent HLA- and infiltrate-related mark rs. Pres nce or absence of soluble
HLA (sHLA) in the aqueous humor of UM-containing eyes compar d t the expression of HLA and
infiltrate related markers as dete mined by qPCR on primary uveal melanoma-tissue. The median is
displayed, with the 95% bootstrap Confidence Intervals (CI).
sHLA
Fluidigm Marker Negative (Median, 95% CI) Positive (Median, 95% CI) p-Value *,§
HLA-A, n = 80 431 (218–834) 1264 (172–2162) 0.07
HLA-B, n = 81 123,245 (81,117–266,604) 205,282 (55,537–1,062,673) 0.46
β2M, n = 70 373,244 (226,274–566,287) 416,625 (22,3013–1,391,012) 0.60
CD40, n = 82 670 (451–1454) 516 (372–869) 0.38
CD8a, n = 69 34 (18–147) 182 (15–1027) 0.73
CD4, n = 71 274 (163–347) 188 (95–380) 0.52
CD3e, n = 65 116 (79–213) 221 (43–1212) 0.78
CD163, n = 79 1023 (509–2000) 839 (484–2404) 0.52
CD68, n = 81 4934 (2989–9072) 5473 (2000–25,873) 1.00
§ Mann–Whitney U test; * test is significant at the 0.05 level (2-tailed).
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When comparing the sHLA-negative group versus the sHLA-positive group regarding the
presence of infiltrate markers (CD40, CD8a, CD4, CD3e, CD163 and CD68) (Mann–Whitney U test),
no significant difference between the two groups was observed (p = 0.38, p = 0.73, p = 0.52, p = 0.78,
p = 0.52 and p = 1.00, respectively) (Table 2). This implies that we found no direct association between
the sHLA expression in the aqueous humour and tumour infiltrate, as one would have expected.
2.4. Tumour Location in Relation to sHLA in Aqueous Humour
We found no correlation between the tumour’s HLA expression and the presence of sHLA in
the aqueous humour, nor any evidence for a relation between the tumour’s infiltrate profile and
the presence of sHLA in aqueous humour. This made us wonder what else might determine the
presence of sHLA. We already noticed that several clinical and genetic prognostic parameters were
strongly associated with the presence of sHLA. We performed a multivariate regression analysis with
data on chromosome 3 status, tumour prominence and involvement of the ciliary body, to see which
characteristic is predominant in determining the presence of sHLA in the aqueous humour (Table 3).
When combining chromosome 3 status, tumour prominence and involvement of the ciliary body in
the multivariate model, both the involvement of the ciliary body and tumour prominence remained
significant (p = 0.02 and p = 0.003, respectively).
Table 3. Univariate and multivariate linear regression analysis on important prognostic tumour
characteristics and sHLA expression in the aqueous humour of UM eyes (n = 108). B stands for the
unstandardised regression coefficient and Beta (β) is the standardised regression coefficient. The β
indicates the effect that a change to the standard deviation (SD) of the independent variable has on the
dependent variable.
sHLA
Variables B (95% CI) Beta (β) p-Value
Univariate regression
Chromosome 3 status (n = 103) 0.17 (0.01–0.31) 0.21 0.034 *
Involvement of ciliary body (n = 108) 2.87 (−0.43–−0.14) −0.36 <0.001 *
Tumour prominence (n = 107) 0.045 (0.02–0.07) 0.36 <0.001 *
Multivariate regression
Model 1
Chromosome 3 status 0.097 (−0.53–0.25) 0.13 0.20
Involvement of ciliary body −0.24 (−0.39–−0.86) −0.30 0.002 *
Model 2
Tumour prominence 0.035 (0.01–0.06) 0.27 0.003 *
Involvement of ciliary body −0.233 (−0.38–−0.09) −0.29 0.002 *
Model 3
Chromosome 3 status 0.44 (0.02–0.07) 0.197 0.035 *
Tumour prominence 0.15 (0.01–0.30) 0.348 <0.001 *
Model 4
Chromosome 3 status 0.10 (−0.46–0.25) 0.13 0.17
Tumour prominence 0.04 (0.01–0.06) 0.28 0.003 *
Involvement of ciliary body −0.18 (−0.34–−0.03) −0.23 0.021 *
* Significant p-values are shown in bold.
3. Discussion
This is the first study describing the presence of sHLA in fluid of the anterior chamber. Due to the
prognostic importance of an inflammatory phenotype in UM, we focused on determining whether the
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soluble form of cell-bound HLA Class I exists in the aqueous humour, and whether it corresponds to
HLA expression on the tumor itself, and which clinical and histopathological characteristics of the
UM determine its presence. We found measurable levels of sHLA in 19/108 of the aqueous humour
samples from UM eyes, but no correlation with the level of expression of HLA in the primary tumour.
However, there were other clear correlations; e.g., between tumour size and location, and with genetics:
The sHLA-positive eyes contained tumours with a significantly larger prominence, which were more
often located in the ciliary body and had a higher AJCC stage. With regard to chromosome status, the
sHLA-positive eyes were significantly more often M3 tumours, with a gain of 8q, and loss of BAP1
protein expression. The association between involvement of the ciliary body and M3 is well known [11].
HLA expressing tumors may release proteins, and the involvement of the ciliary body especially may
lead to leakage of sHLA and other proteins into the aqueous humor. Previous studies that focused on
vitreous fluid found correlations between several cytokines and tumor prominence, as well as to T-cell
infiltrate and macrophage infiltration [31].
Most studies on the presence of sHLA, in serum samples from metastatic cutaneous malignant
melanoma patients, focus on the sHLA form of HLA-G and not on HLA-A/B [32]. Studies on HIV
infection, autoimmune disease, but also cutaneous melanoma and renal cell carcinoma, have shown
that sHLA levels in serum correlate to disease progression [33–36]. This aligns with our finding that
more aggressive tumours especially, have positive levels of sHLA in the aqueous humor. As it was
already hard to find sHLA in aqueous samples, we did not analyse serum samples from patients with
an intraocular UM. A future study might look at serum from patients with UM metastases.
Current treatment options for metastatic UM are limited, but new therapies based on immunologic
principles are being developed. One study on glioblastoma describes the potential of sHLA as the
basis to identify potential biomarkers for disease detection and treatment [24]. sHLA molecules
carry their original tumour-derived bound peptides. It was found that the immunopeptidomes
of the sHLA molecules of cancer patients are very different with disproportionally-sized fractions
of peptides originating from the tumour cells. It is hypothesised that this could help to identify
tumour antigens, presented by the circulating sHLA complexes in the blood. Since UM spreads via
the hematogenous route, plasma could be used to detect cancer biomarkers for early detection or
monitoring [24]. One study on the topic of mass spectrometric identification investigated the capture of
sHLA complexes and recovery of peptides from cell lines and serum of metastatic cutaneous melanoma
patients. They found 972 different peptides in the sera of patients of which some were related to the
melanocytic tumour, as previously described [37]. They stress that knowledge of the peptides may
have important implications; e.g., in tumor rejection in immunotherapy.
Other studies focus on the mechanism by which sHLA plays a part in tumor-escape. It is thought
that sHLA Class I molecules induce apoptosis of cytolytic effector cells; e.g., Natural Killer (NK) cells
and CD8+ T lymphocytes [30,38,39].
A limitation of this study is the absence of a comparison of aqueous humor of UM eyes to normal
eyes and eyes with other conditions. We tested a limited number of ocular fluids from normal eyes that
underwent cataract surgery, and obtained negative results, which was expected as previous studies
have shown low or undetectable levels of a wide range of cytokines in the normal aqueous humor [40].
Now that we have developed a test for sHLA, it will be interesting to expand testing of aqueous and
vitreous for sHLA to eyes with different types of uveitis or with ocular lymphoma, as in both diseases,
many different cytokines are being expressed in the aqueous humor [41].
Another limitation of this study is that the aqueous samples were only acquired from enucleated
eyes, of which the tumours are usually large. It would be interesting to expand this analysis to eyes
undergoing irradiation treatment. Additionally, as this assay detects the backbone of the HLA Class I
molecule, while another addition would be to expand the assay to detect different HLA alleles to see
whether they are expressed at the same level.
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4. Materials and Methods
4.1. Patient Population
This study was conducted at the department of Ophthalmology, Leiden University Medical Center
(LUMC), Leiden, The Netherlands. Aqueous humour samples were obtained from eyes of 108 UM
patients who had been enucleated at the LUMC, between 1999 and 2017. Clinical patient information
and data on survival were obtained from patient charts and the Dutch National Cancer Registry, and
collected in a database. Follow-up time was defined as the time period between the date of enucleation
and the moment of death or the last recorded follow-up moment. Data was updated in June 2019.
Of the 108 patients, 45 had died from metastases, 19 from other causes and 44 were still alive at the end
of follow-up.
Enucleated eyes underwent conventional histopathological evaluation by a pathologist specialised
in ocular pathology. Tumour, lymph node and metastases (TNM) were staged in accordance with the
8th edition of the American Joint Committee on Cancer (AJCC) staging manual [42].
4.2. Collection of Aqueous Humour
Directly following enucleation, an anterior chamber puncture was performed to collect a sample
of aqueous humour, using a 23 Gauge needle, and samples were directly stored at −80 ◦C. Additionally,
a tumour sample was collected for cytogenetic analysis, as well as for DNA and/or mRNA analysis.
Tumour tissue was fixed in 4% neutral buffered formalin for at least 48 h, dehydrated and embedded
in paraffin.
4.3. Luminex Assay
Soluble HLA Class I in the anterior chamber fluid was measured using an in-house developed
assay and optimised for use with aqueous humour. This assay uses magnetic beads coupled to
anti-HLA-Class I directed, and purified W6/32 antibody (Department of Immunohematology, LUMC,
The Netherlands), and the detection antibody anti- β2M-PE (BD Pharmingen; 551337). The Bio-Plex
LuminexTM system (Bio-Rad, Hercules, CA, USA) was used for read-out.
Measuring the levels of sHLA in aqueous humour by magnetic Luminex assay was newly
developed, and is based on a previously-described assay [43]. First, aqueous humour samples
were thawed and centrifuged for 4 min at 1400 rpm, after which samples were 1:1 diluted with
1% Bovine Serum Albumin/Phosphate Buffered-Saline (BSA/PBS) to obtain a concentration of 0.5%
BSA/PBS. A calibration line with Dimer XI was prepared in 0.5% BSA/PBS. The beads were diluted to a
concentration of 2500 beads per well in Assay Buffer (Diluent and Reagent kit III, Bio-Rad, Hercules,
CA, USA) and washed twice with 80 µL wash water. Twenty microlitres of a calibration sample,
a diluted test sample, or 0.5% BSA/PBS (blank) was added to each well of a 96-well plate, followed by
incubation on a shaker, protected from light, at room temperature, for 45 min. Following three washes,
the detection Ab (diluted 1:100 in detection Ab diluent) and 15 µL of this mixture were added to each
well. The plate was incubated on a shaker, protected from light, at room temperature, for 30 min.
Finally, the plate was washed three times with 80 µL wash buffer followed by adding 80 µL of assay
buffer to each well. The plate was placed on a shaker until measurement (or stored at 4 ◦C).
As this was the first time that aqueous humour samples were tested, optimal dilutions were
determined first. The test values were interpolated in the calibration line. Samples below the lower
limit of quantification were categorised as negative.
4.4. Chromosome Status and BAP1 Immunohistochemistry
For the 108 samples included in this study, three different cytogenetic tests were performed to
determine the tumours’ chromosome statuses. On 36/108 tumours, both karyotyping and fluorescence
in situ hybridisation (FISH) analysis with the use of DNA probes designed specifically for the centromere
of chromosome 3, were performed. Twenty-three Tumours were analysed using a genome wide
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micro-array analysis of single-nucleotide polymorphisms (SNPs), performed with the Affymetrix 250K
Nsp array (Affymetrix, Santa Clara, CA, USA), as previously described [44]. A total of 45 tumours
was tested with all three techniques. In case of a disagreement between the three cytogenetic tests,
tumours were defined as having monosomy 3 or a gain of 8q when any of the three before-mentioned
tests showed this chromosomal aberration. Immunohistochemistry (IHC) of BAP1 was performed as
previously described [44,45] and scored by an ocular pathologist.
4.5. qPCR Analysis Using Fluidigm Array
A qPCR Fluidigm 96.96 dynamic array (FLUIDIGM Corporation, South San Francisco, CA,
USA) was performed on tissue from 94 tumours. RNA isolation and quality checks were performed
as previously described [46]. Total RNA (50–200 ng) was used for cDNA synthesis, following the
manufacturer’s manuals. Ten-times diluted cDNA (1.25 µL) was pre-amplified containing 2.5 µL of
Taqman Preamp master mix (Applied Biosystems, Foster City, CA, USA) and 1.25 µL of pooled primer
mix for 14 cycles. The qPCR reactions were performed using Eva-green dye following the Fluidigm
protocol, and results were collected on the BioMark HD system (FLUIDIGM). Absolute Cq values from
duplicate measurements of each transcript were averaged, and relative gene expression levels were
normalised to the geometric mean of the reference genes glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), β-actin, Hypoxanthine Phosphoribosyltransferase 1 (HPRT-1), Ribosomal Protein L13a
(RPL13a) and Hydroxymethylbilane Synthase (HMBS).
4.6. Statistical Analyses
Statistical analyses were performed using SPSS software (IBM Corp. Released 2015. IBM SPSS
Statistics for Windows, Version 23.0. Armonk, NY, USA). The Pearson chi-square test was used
to analyse categorical data and a Linear-by-Linear Association was used in case of more than two
categories. The Mann–Whitney U Test was used as a non-parametric test to compare two groups.
For multivariate analysis, a multivariate linear regression was conducted. Kaplan–Meier curves were
made to analyse survival, with the log rank test to compare groups and were drawn using GraphPad
Prism version 5.00 for Windows, GraphPad Software, La Jolla, CA, USA. p values of <0.05 were
considered statistically significant.
4.7. Study Approval
This study was approved by the Biobank Committee of the LUMC (number:
Uveamelanoomlab-2019-5, date of approval: 20th May 2019). The research adhered to Dutch law
and the tenets of the Declaration of Helsinki (World Medical Association of Declaration 2013; ethical
principles for medical research involving human subjects).
5. Conclusions
Soluble HLA is especially present in the aqueous humour of large tumours, which display ciliary
body involvement, loss of chromosome 3, and negative BAP1 staining, and which have a higher chance
of developing metastases. As sHLA is related to metastasis development, the presence of detectable
levels of sHLA in the aqueous humour may aid in selecting cases for future adjuvant trials or aid in
prognostication, without having to take tumour material from mateiral or a tumour biopsy.
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